Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol.

Does a complex intervention increase patient knowledge about oral anticoagulation? - a cluster-randomised controlled trial. BMC Fam Pract (2017) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res (2008) 4.25

Estimating treatment effects using observational data. JAMA (2007) 4.12

Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol (2003) 3.51

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg (2014) 3.46

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (2015) 2.83

Beyond the intention-to-treat in comparative effectiveness research. Clin Trials (2011) 2.65

Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med (2013) 2.14

Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost (2008) 2.05

Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care (2010) 1.88

Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology (1996) 1.87

Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res (2005) 1.87

Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med (2014) 1.46

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther (2015) 1.45

A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review. Int J Biostat (2011) 1.28

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis (2013) 1.20

Ethical considerations in studying drug safety--the Institute of Medicine report. N Engl J Med (2012) 1.10

Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc (2015) 1.06

Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study. Circulation (2015) 1.01

Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am Heart J (2015) 1.00

Warfarin and intracranial haemorrhage. Blood Rev (2008) 0.99

Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood) (2010) 0.95

Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther (2015) 0.88